To support the advancement of the next generation of kinase-targeted therapeutic programs, SignalChem has developed over 50 clinically relevant active EGFR mutants, representing the most comprehensive list of this class of proteins in the industry. Epidermal Growth Factor Receptor (EGFR) is an important trans-membrane Receptor Tyrosine Kinase extensively recognized for the role it plays in Cancer. Mutations in the EGFR encoding gene can compromise its biological function resulting in deregulation of key cell-signaling pathways. These alterations are the driving agents in many cancers as non-small cell lung cancer, glioblastoma, and basal-like breast cancer.
Tyrosine kinase inhibitors, targeting critical EGFR mutations have revolutionized targeted therapeutics of multiple key cancers such as non-small cell lung cancer (NSCLC) and has established EGFR's as important drug targets. Furthermore, researchers are constantly being challenged by resistance to EGFR targeting cancer therapies, as a result, altering the clinical implications of these anti-EGFR treatments and drug discovery projects. To tackle these challenges, and aide the global life science community, SignalChem has utilized our protein kinase experts with over 100 years of combined experience in developing an effective line of biologically active recombinant EGFR mutants for the international research community.